ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Lymphoid-Tissue-on-Chip Recapitulates Human Antibody Responses In Vitro.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract-the B Cell Side.Allergy · 2026Review
- Organoid: a promising solution to current challenges in cancer immunotherapy.npj biomedical innovations · 2025Review
- Integration of lymphatic vasculature to a human lymph node-on-chip enhances physiological immune properties.Materials today. Bio · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Reliable modeling of human adaptive immune responses is a prerequisite to understand processes leading to vaccine-induced protective immunization, to overcome the poor predictive value of non-clinical in vivo and in vitro models and to drive informed decisions in vaccine development pipelines. Here, we present a centrifugal microfluidics-based organ-on-chip approach to generate an organotypic high density lymphoid-tissue-on-chip. The model enables long-term culture of lymphoid tissue while preventing autoactivation and shows raised antigen-specific antibody responses against influenza vaccines for up to 4 weeks on-chip. Antibody response of different magnitude and quality could be induced both by direct antigen exposure as well as by recruitment of peripheral antigen-presenting cells. The model represents an attractive approach to evaluate the impact of the mode of antigen delivery on adaptive immune responses. Beyond applications in vaccine development, the lymphoid-tissue-on-chip provides a platform to study cellular interactions during homeostasis, immune responses, and drug treatment over several weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.